Trials / Terminated
TerminatedNCT04727632
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE: Functional Precision Oncology for Metastatic Breast Cancer Feasibility Trial
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]Fluoroestradiol (FES) PET/CT | \[18F\]Fluoroestradiol (FES) PET/CT |
Timeline
- Start date
- 2021-03-31
- Primary completion
- 2023-09-14
- Completion
- 2024-07-30
- First posted
- 2021-01-27
- Last updated
- 2024-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04727632. Inclusion in this directory is not an endorsement.